MedTrace Logo

A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

NCT03604224 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 178

Last updated 2020-08-19

No results posted yet for this study

Summary

The purpose of this study is to observe clinical effectiveness of canagliflozin by mean haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2 diabetes participants.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Canagliflozin 300 mg

Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.

Sponsors & Collaborators

  • Johnson & Johnson Private Limited

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Private Limited Clinical Trial · Johnson & Johnson Private Limited

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2019-07-01
Completion
2019-07-01
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604224 on ClinicalTrials.gov